Telomir Pharmaceuticals, INC. (TELO) — SEC Filings

Overview

Telomir Pharmaceuticals, INC. (TELO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 24, 2026: Telomir Pharmaceuticals, Inc. filed an 8-K on April 24, 2026, reporting on April 22, 2026, regarding a material definitive agreement, completion of an acquisition or disposition of assets, and unregistered sales of equity securities. The filing also includes financial statements and exhibits.

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 49 neutral, 1 mixed. The dominant filing sentiment for Telomir Pharmaceuticals, INC. is neutral.

Filing Type Overview

Telomir Pharmaceuticals, INC. (TELO) has filed 43 8-K, 6 10-Q, 1 10-K with the SEC between May 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• Telomir Pharma Files 8-K on Agreements and Acquisitions — 8-K · Apr 24, 2026 Risk: medium
  Telomir Pharmaceuticals, Inc. filed an 8-K on April 24, 2026, reporting on April 22, 2026, regarding a material definitive agreement, completion of an acquisiti
• Telomir Pharmaceuticals Files 8-K — 8-K · Mar 31, 2026 Risk: low
  Telomir Pharmaceuticals, Inc. filed an 8-K on March 31, 2026, reporting other events as of March 30, 2026. The filing does not contain specific details on the n
• Telomir Pharmaceuticals Reports Board and Executive Compensation Changes — 8-K · Dec 22, 2025 Risk: medium
  Telomir Pharmaceuticals, Inc. announced on December 17, 2025, a change in its board of directors and executive compensation arrangements. Specifically, the comp
• 8-K Filing — 8-K · Dec 17, 2025
• 8-K Filing — 8-K · Nov 24, 2025
• 8-K Filing — 8-K · Nov 20, 2025
• 8-K Filing — 8-K · Nov 12, 2025
• Telomir Narrows Loss to $8.35M, Boosts Cash with $8.55M Financing — 10-Q · Nov 10, 2025 Risk: high
  Telomir Pharmaceuticals, Inc. (TELO) reported a net loss of $8.35 million for the nine months ended September 30, 2025, a significant improvement from the $13.6
• Telomir Pharmaceuticals Files 8-K — 8-K · Oct 22, 2025 Risk: medium
  On October 22, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific detai
• Telomir Pharmaceuticals Enters Material Definitive Agreement — 8-K · Oct 20, 2025 Risk: medium
  On October 17, 2025, Telomir Pharmaceuticals, Inc. entered into a material definitive agreement. The company, incorporated in Florida with its principal executi
• Telomir Pharmaceuticals Files 8-K Report — 8-K · Oct 14, 2025 Risk: low
  On October 14, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific finan
• Telomir Pharmaceuticals Files 8-K Report — 8-K · Oct 8, 2025 Risk: low
  On October 8, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates the company is incorporated in Florida and its principal executive o
• Telomir Pharmaceuticals Files 8-K Report — 8-K · Oct 6, 2025 Risk: low
  On October 6, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. The company is inc
• Telomir Pharmaceuticals Files 8-K Report — 8-K · Sep 18, 2025 Risk: low
  On September 18, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates that the company is located at 100 SE 2nd St, Suite 2000 #1009, M
• Telomir Pharmaceuticals Files 8-K — 8-K · Sep 9, 2025 Risk: low
  On September 9, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific deta
• Telomir Pharmaceuticals Files 8-K — 8-K · Sep 4, 2025 Risk: medium
  Telomir Pharmaceuticals, Inc. filed an 8-K on September 4, 2025, reporting an event on August 28, 2025. The filing is categorized under 'Other Events' and does
• Telomir Pharmaceuticals Files 8-K — 8-K · Aug 27, 2025 Risk: medium
  Telomir Pharmaceuticals, Inc. filed an 8-K on August 27, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these
• Telomir Pharmaceuticals Files 10-Q for Q2 2025 — 10-Q · Aug 14, 2025 Risk: medium
  Telomir Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2025. The company, based in Miami, FL, operates in the pharmaceutical preparations s
• Telomir Pharmaceuticals Files 8-K — 8-K · Aug 7, 2025 Risk: low
  On August 7, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates that the company is involved in the pharmaceutical preparations indus
• Telomir Pharmaceuticals Files 8-K Report — 8-K · Jul 23, 2025 Risk: medium
  On July 23, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific details
• Telomir Pharmaceuticals Files 8-K: Other Events — 8-K · Jul 22, 2025 Risk: medium
  On July 18, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates an 'Other Events' item, but provides no further specific details regar
• Telomir Pharmaceuticals Files 8-K with Corporate Details — 8-K · Jul 17, 2025 Risk: low
  On July 17, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates that the company is located at 100 SE 2nd St, Suite 2000 #1009, Miami,
• Telomir Pharmaceuticals Files 8-K Report — 8-K · Jun 18, 2025 Risk: medium
  On June 18, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific details
• Telomir Pharmaceuticals Files 8-K — 8-K · Jun 11, 2025 Risk: low
  On June 11, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns administrative details and does not disclose any new material
• Telomir Pharmaceuticals Files 8-K Report — 8-K · Jun 5, 2025 Risk: medium
  On June 5, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates an 'Other Events' item, suggesting a significant development not covere
• Telomir Pharmaceuticals Files 8-K — 8-K · Jun 2, 2025 Risk: medium
  On June 2, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific details r
• Telomir Pharmaceuticals Files 8-K — 8-K · May 29, 2025 Risk: low
  On May 29, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates that the company is located in Miami, Florida, and operates within the
• Telomir Pharmaceuticals Reports Equity Sale — 8-K · May 21, 2025 Risk: medium
  On May 19, 2025, Telomir Pharmaceuticals, Inc. reported an unregistered sale of equity securities. The company also disclosed other events, though specific deta
• Telomir Pharmaceuticals Files 8-K — 8-K · May 15, 2025 Risk: medium
  Telomir Pharmaceuticals, Inc. filed an 8-K on May 15, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these eve
• Telomir Pharmaceuticals Files Q1 2025 10-Q — 10-Q · May 14, 2025 Risk: medium
  Telomir Pharmaceuticals, Inc. filed its quarterly report for the period ending March 31, 2025. The company, based in Miami, Florida, operates in the pharmaceuti
• Telomir Pharmaceuticals Files 8-K — 8-K · May 7, 2025 Risk: medium
  Telomir Pharmaceuticals, Inc. filed an 8-K on May 7, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these even
• Telomir Pharmaceuticals Files 8-K — 8-K · Mar 19, 2025 Risk: medium
  Telomir Pharmaceuticals, Inc. filed an 8-K on March 19, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these e
• Telomir Pharmaceuticals Files 8-K Report — 8-K · Feb 25, 2025 Risk: low
  On February 25, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates the company is incorporated in Florida and its principal executive
• Telomir Pharmaceuticals Files 8-K — 8-K · Feb 20, 2025 Risk: low
  On February 20, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates that the company is located at 100 SE 2nd St, Suite 2000 #1009, Mi
• Telomir Pharmaceuticals Files 8-K — 8-K · Feb 18, 2025 Risk: low
  Telomir Pharmaceuticals, Inc. filed an 8-K on February 18, 2025, reporting "Other Events." The filing does not contain specific details about the nature of thes
• Telomir Pharmaceuticals Files 2024 10-K — 10-K · Feb 4, 2025 Risk: medium
  Telomir Pharmaceuticals, Inc. filed its 2024 10-K on February 4, 2025, reporting on its fiscal year ending December 31, 2024. The company, based in Miami, Flori
• Telomir Pharmaceuticals Files 8-K Report — 8-K · Jan 28, 2025 Risk: medium
  On January 28, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific detai
• Telomir Pharmaceuticals Files 8-K — 8-K · Jan 7, 2025 Risk: low
  On January 7, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates that the company is located at 100 SE 2nd St, Suite 2000, #1009, Mia
• Telomir Pharmaceuticals Files 8-K — 8-K · Dec 23, 2024 Risk: medium
  Telomir Pharmaceuticals, Inc. filed an 8-K on December 23, 2024, reporting "Other Events." The filing does not contain specific details about the nature of thes
• Telomir Pharmaceuticals Changes Accountants — 8-K · Dec 20, 2024 Risk: medium
  Telomir Pharmaceuticals, Inc. announced on December 16, 2024, a change in its certifying accountant. The company has dismissed its previous independent register
• Telomir Pharmaceuticals Sells $500K in Stock — 8-K · Dec 11, 2024 Risk: medium
  Telomir Pharmaceuticals, Inc. announced on December 9, 2024, that it entered into a securities purchase agreement for the sale of 1,000,000 shares of its common
• Telomir Pharmaceuticals Files 8-K — 8-K · Dec 2, 2024 Risk: medium
  Telomir Pharmaceuticals, Inc. filed an 8-K on December 2, 2024, reporting "Other Events." The filing does not contain specific details about the nature of these
• Telomir Pharmaceuticals Announces Board and Officer Changes — 8-K · Nov 21, 2024 Risk: medium
  Telomir Pharmaceuticals, Inc. announced on November 18, 2024, changes in its board of directors and officer appointments. Specifically, the company elected new
• Telomir Pharmaceuticals Files 8-K — 8-K · Nov 20, 2024 Risk: medium
  Telomir Pharmaceuticals, Inc. filed an 8-K on November 20, 2024, reporting "Other Events." The filing does not contain specific details about the nature of thes
• Telomir Pharmaceuticals Files Q3 2024 10-Q — 10-Q · Nov 12, 2024 Risk: low
  Telomir Pharmaceuticals, Inc. filed a 10-Q for the period ending September 30, 2024. The company, incorporated in Florida, operates in the pharmaceutical prepar
• Telomir Pharmaceuticals Enters Material Agreement with 03 Life Sciences — 8-K · Sep 27, 2024 Risk: medium
  On September 24, 2024, Telomir Pharmaceuticals, Inc. entered into a Material Definitive Agreement with 03 Life Sciences. This agreement involves a direct financ
• Telomir Pharmaceuticals Files 8-K — 8-K · Sep 3, 2024 Risk: low
  Telomir Pharmaceuticals, Inc. filed an 8-K on September 3, 2024, reporting an "Other Events" item. The filing does not contain specific details about the event,
• Telomir Pharmaceuticals Files Q2 2024 10-Q — 10-Q · Aug 13, 2024 Risk: medium
  Telomir Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The company, located at 900 West Platt Street, Suite 200, Tampa, FL 33606, ope
• Telomir Pharmaceuticals Changes HQ, Reports Officer Compensation — 8-K · Jun 24, 2024 Risk: low
  Telomir Pharmaceuticals, Inc. announced on June 18, 2024, a change in its principal executive offices to Baltimore, Maryland. The company also reported on compe
• Telomir Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 13, 2024 Risk: low
  Telomir Pharmaceuticals, Inc. (TELO) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Telomir Pharmaceuticals, Inc. filed a 10-Q report for the per

Risk Profile

Risk Assessment: Of TELO's 46 recent filings, 1 were flagged as high-risk, 27 as medium-risk, and 18 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Telomir Pharmaceuticals, INC.'s most recent 10-Q filing (Nov 10, 2025):

• Revenue: $0
• Net Income: -$8.35M
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: $7.33M
• Operating Margin: N/A
• Total Assets: N/A
• Total Debt: N/A

Key Executives

• Jonnie R. Williams, Sr.

Industry Context

Telomir Pharmaceuticals operates in the biotechnology sector, specifically focusing on pre-clinical drug development. This industry is characterized by high research and development costs, long development cycles, significant regulatory oversight, and a high rate of failure. Success is heavily dependent on scientific innovation, intellectual property protection, and the ability to secure substantial funding for clinical trials and eventual commercialization.

Top Tags

8-K (13) · 8-k (12) · other-events (12) · pharmaceuticals (9) · disclosure (7) · corporate-filing (4) · sec-filing (4) · filing (4) · regulatory-filing (3) · 10-Q (3)

Key Numbers

• CIK Number: 0001971532 — Identifies Telomir Pharmaceuticals, Inc. in SEC filings.
• Filing Date: 2026-04-24 — Date the 8-K was officially filed with the SEC.
• Cash: $7.33M — Increased from $1.27M at Dec 31, 2024, due to financing activities.
• Net Loss: $8.35M — Improved from $13.63M in the prior year period.
• Cash from Financing: $8.55M — Key driver of increased cash balance, including related party and common stock sales.
• Cash Used in Operations: $2.49M — For the nine months ended September 30, 2025.
• Common Stock Shares Outstanding: 33,830,971 — As of September 30, 2025, up from 29,762,671 at Dec 31, 2024.
• Royalty Rate: 8% — Payable to MIRALOGX, LLC on net sales of Licensed Products.
• Total Stockholders' Equity: $6.98M — As of September 30, 2025, up from $0.64M at Dec 31, 2024.
• Research and Development Expenses: $1.14M — For the nine months ended September 30, 2025, down from $1.97M.
• SEC File Number: 001-41952 — Identifies the company's filing with the SEC.
• IRS Employer Identification No.: 87-2606031 — Company's tax identification number.
• Reporting Period End Date: 20250630 — Indicates the end of the fiscal quarter covered by the report.
• Reporting Period: Q1 2025 — The first quarter of 2025, for which financial information is reported.
• Fiscal Year End: 2024-12-31 — Reporting period for the 10-K

Frequently Asked Questions